<DOC>
	<DOCNO>NCT01993472</DOCNO>
	<brief_summary>The purpose study determine efficacy safety Andrographolides combine Capecitabine treatment elderly patient locally advanced recurrent metastasis inoperable colorectal cancer</brief_summary>
	<brief_title>Study Andrographolides With Without Capecitabine Treat Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Andrographolide</mesh_term>
	<criteria>1 . Histologically cytologically confirm diagnosis adenocarcinoma colon rectum 2 . Locally advanced recurrent metastasis inoperable disease 3 . At least 1 measurable nonmeasurable lesion per RECIST version 1.1 guideline . Lesion must choose previously irradiate field unless documented tumor progression lesion prior randomization . All sit disease must evaluate ≤ 28 day prior randomization . 4 . Man woman ≥ 65 year age 5 . Hematological function , follow : ( ≤ 10 day prior randomization ) Absolute neutrophil count ( ANC ) ≥ 1.5×109/L Platelet count ≥ 75×109/L Hemoglobin ≥ 8.0 g/dL 6 . Renal function , follow : ( ≤ 10 day prior randomization ) Creatinine≤ 1.5×ULN 7 . Hepatic function , follow : ( ≤ 10 day prior randomization ) Aspartate aminotransferase ( AST ) ≤ 3×ULN ( liver metastases≤ 5×ULN ) Alanine aminotransferase ( ALT ) ≤ 3×ULN ( liver metastases≤ 5×ULN ) Total bilirubin≤ 1.5×ULN 8 . Subject subject 's legally acceptable representative provide informed consent 1 . Symptomatic brain metastasis require treatment 2 . History malignancy , except : Malignancy treat curative intent know active disease present ≥ 5 year prior randomization felt low risk recurrence treat physician Adequately treat nonmelanomatous skin cancer lentigo maligna without evidence disease Adequately treat cervical carcinoma situ without evidence disease Prostatic intraepithelial neoplasia without evidence prostate cancer 3 . Antitumor therapy ( eg , chemotherapy , hormonal therapy , immunotherapy , antibody therapy ) ≤ 21 day randomization . Subjects must recover acute radiotherapyrelated toxicity 4 . Radiotherapy≤ 14 day randomization . Subjects must recover acute radiotherapyrelated toxicity 5 . Clinically significant cardiovascular disease ( include myocardial infarction , unstable angina , symptomatic congestive heart failure , serious uncontrolled cardiac arrhythmia ) ≤ 6 month prior randomization 6 . History interstitial lung disease ( ILD ) eg , interstitial pneumonitis , pulmonary fibrosis evidence ILD baseline chest CT MRI 7 . History medical psychiatric condition labortory abnomality opinion investigator may increase risk associate study participation investigational product administration may interfere interpretation result 8 . Unstable pulmonary embolism , deep vein thrombosis , significant arterial/venous thromboembolic event ≤ 30 day randomization . If anticoagulation , subject must stable therapeutic dose prior rangdomization . 9 . Subject kind disorder compromise ability subject give write informed consent and/or comply study procedure unwilling unable comply study requirement</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>